Metrics as of 10/17/2026, 08:26 AM (Berlin time), refresh in progress.
Pharvaris Stock
Pharvaris N.V.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- CEO
- Berndt Modig
- Employees
- 148
- Market cap
- $1.9 B
- IPO
- 04/02/2021
Pharvaris N.V. operates in the Healthcare / Biotechnology sector, specializing in the development and commercialization of therapies for rare diseases with high unmet medical needs. The company focuses on treating patients with angioedema as well as other bradykinin-mediated conditions. A central element of its…
AI-generated company profile based on the figures on this page, last updated on 04/08/2026. Not investment advice.
Pharvaris stock: price history
1D
-6.4%
1W
-10.8%
1M
-26.1%
6M
-2.9%
YTD
-0.0%
1Y
+26.9%
2Y
+29.0%
5Y
+75.6%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~168% stronger price swings than usual
Pharvaris stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Pharvaris N.V. is a late-stage biopharma company specialized in developing and commercializing therapies for rare diseases, with a focus on treating angioedema and other bradykinin-mediated diseases. A central component of its pipeline is the molecule Deucrictibant, which is currently in Phase 3 trials for the treatment and prophylaxis of attacks in hereditary angioedema. The business model is based on selling specialized pharmaceutical active substances to patients with unmet medical needs.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Pharvaris
Analyst assessment of Pharvaris
PRICE TARGET LOW
US$44.00
CONSENSUS
US$60.73
MEDIAN
US$62.00
PRICE TARGET HIGH
US$75.00
0
STRONG BUY
13
BUY
1
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 10/09/2026
Pharvaris stock metrics
P/E
-9.14
P/B
5.59
EV/EBITDA
-8.17
RETURN ON EQUITY
-15.9%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
48.1%
FLOAT SHARES
33,602,274
AVG. DAILY VOLUME (30D)
999,652
Insider transactions (SEC)
Lu Peng
Lu Peng
Monges Viviane
Monges Viviane
Schikan Johannes Gerardus Christiaan Petrus
Attention
Price since yesterday: -6.4%
Search (Google Trends)
Institutional holders
Comparable stocks
Frequently asked questions about Pharvaris stock
What does Pharvaris do?
Pharvaris N.V. is a company in the Healthcare sector, Biotechnology industry, headquartered in Switzerland.
The CEO is Berndt Modig, the company employs around 148 people.
The IPO was on 04/02/2021; the stock trades on NASDAQ under the ticker PHVS.
What do analysts say about Pharvaris stock?
14 analysts rate the stock, the consensus is Buy (as of 10/09/2026).
The average price target is US$60.73, ranging from US$44.00 to US$75.00, with a median of US$62.00.
This is an external assessment, not a statement by Market Jury.
When does Pharvaris report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 168% stronger than usual.
Does Pharvaris pay a dividend?
No, Pharvaris currently does not pay a dividend.
Which stocks are comparable to Pharvaris?
Comparable stocks include BeOne Medicines, Idorsia, Basilea Pharmaceutica, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx and Revolution Medicines.
How can I get Pharvaris stock analyzed?
Clicking "Analyze stock" lets five strategies assess Pharvaris against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.